IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#673
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$51.1B
Jonathan J. Mazelsky
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for companion animal veterinary, livestock and poultry, dairy, and water testing markets. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides veterinary diagnostic products, including instruments, consumables, and rapid assay test kits.
Headcount
10.8K
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = IDXX ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$IDXX IDEXX LABORATORIES INC /DE | 60 | 79 | 60 | 56 | 47.7x | 36.3x | 65.0% | 31.2% | 62.0% | 32.1% | 24.9% | 10.1% | 0.0% | 28.0x | $51.1B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
IDEXX LABORATORIES INC /DE (IDXX) receives a "Hold" rating with a composite score of 60.2/100. It ranks #673 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
HQ Base
Westbrook, Maine
In-line with peers — no strong momentum signal
Fair valuation relative to peers
High profitability & efficiency — strong quality floor supports entry
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for IDXX.
View All RatingsROIC 452.1% vs WACC 9.7% (spread +442.4%)
GM 62% vs sector 44%, OM 32% vs sector 3%
Capital turnover 17.80x, R&D intensity 5.8%
Rev growth 10%, 10yr history
Interest coverage 127.6x, Net debt/EBITDA 0.2x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate IDEXX LABORATORIES INC /DE (IDXX) as a Hold with a composite score of 60.2/100 at a current price of $647.70. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
IDEXX LABORATORIES INC /DE holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 60.2/100 places it at rank #673 in our full universe.
Wide
Low
Exemplary
Fair Value
Gross margins of 62% signal strong pricing power.
Returns on equity of 65.0% exceed cost of capital.
Stable competitive position in a defensive sector.
Elevated P/E ratio of 47.7x leaves little room for execution misses.
Vulnerability to macroeconomic shocks and interest rate volatility.
IDEXX LABORATORIES INC /DE represents a hold based on multi-factor quantitative performance.
Our model assigns IDEXX LABORATORIES INC /DE a Hold rating, with a composite score of 60.2/100 and 3 out of 5 stars. Ranked #673 of 7,333 stocks, IDXX presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
IDXX earns a quality score of 79/100, indicating above-average business quality. The company reports a return on equity of 65.0% (sector avg: -1.9%), gross margins of 62.0% (sector avg: 44.1%), net margins of 24.9% (sector avg: 1.0%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
IDXX's value score of 60/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 47.66x, an EV/EBITDA of 36.27x, a P/B ratio of 30.99x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
IDEXX LABORATORIES INC /DE's investment score of 32/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 10.1% vs. a sector average of 6.7% and a return on assets of 31.2% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
IDXX demonstrates moderate momentum with a score of 56/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 10.1% year-over-year, while a beta of 1.02 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
IDXX shows good financial stability with a score of 75/100. Key stability metrics include a beta of 1.02 and a debt-to-equity ratio of 28.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
The short interest score of 56/100 for IDXX suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 28.00x). With a $51.1B market cap (large-cap), IDEXX LABORATORIES INC /DE may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
IDEXX LABORATORIES INC /DE is a large-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #673 of 7,333 overall (91st percentile). Key comparisons include ROE of 65.0% exceeding the -1.9% sector median and operating margins of 32.1% above the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While IDXX currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Quality (79) vs Investment (32) — closing this gap could shift the rating.
EV/EBITDA 216% ABOVE SECTOR MEDIAN
ROE 3523% BELOW SECTOR MEDIAN
Gross Margin 41% ABOVE SECTOR MEDIAN (FAVORABLE)
Above 50MA
37.18%
Net New Highs
+51081
The $51.1B question: What happens when a company this good becomes this expensive? In the constellation of American capitalism, certain companies shine brighter than others — not because they are inherently more valuable, but because they have positioned themselves at the nexus of forces that shape the economy. IDEXX LABORATORIES INC /DE is one such company. At $51.1B in market capitalization, IDEXX LABORATORIES INC /DE (IDXX) currently ranks #209 in our quantitative model, with a compos
Five S&P 500 stocks outperformed in August 2025, including Albemarle, UnitedHealth Group, Intel, Humana, and Idexx Laboratories, each with unique factors driving their stock price increases.
Idexx Laboratories is the global leader in pet healthcare diagnostics, generating substantial recurring revenue from its installed base of diagnostic equipment. Despite its impressive growth and profitability, the company's share price has languished, presenting an opportunity for investors as management ramps up share buybacks at a historically low valuation.
New directors bring decades of financial leadership and board experience to enhance strategic oversight of Return-to-Growth action plan and long-term value creationCHARLOTTE, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced the appointments of James (Jim) D. Forbes and Brian P. McKeon to its Board of Directors (the “Board”), effective February 27, 2026. Mr. Forbes is a veteran healthcare investment banker with 30 yea
IDEXX Laboratories (NasdaqGS:IDXX) has announced that long-serving board member M. Anne Szostak will retire following the 2026 Annual Meeting of Stockholders. The company has recently appointed Michael G. Erickson, PhD, to its Board of Directors as part of an upcoming refresh in board composition. These board changes come as IDEXX trades at a share price of $623.13 and continues to adjust its governance structure. IDEXX Laboratories, trading on the NasdaqGS under the ticker IDXX, currently...